Hoth Therapeutics Expands Patent Portfolio for HT-001 to Combat Severe Skin Toxicities in Oncology Treatments Hoth Therapeutics has announced the expansion of its patent filings for HT-001, targeting skin toxicities related to cancer therapies, enhancing patient care and drug efficacy.

Hoth Therapeutics Expands Patent Portfolio for HT-001 to Combat Severe Skin Toxicities in Oncology Treatments #USA #New_York #Hoth_Therapeutics #HT-001 #Menin_Inhibitors

Menin Inhibitors: Transforming Hematologic Oncology for the Next Decade An in-depth analysis of the menin inhibitors market reveals significant growth potential, driven by innovations in hematologic oncology and targeted therapies.

Menin Inhibitors: Transforming Hematologic Oncology for the Next Decade #United_States #Las_Vegas #Revumenib #Hematologic_Oncology #Menin_Inhibitors